help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Endocrinology, doi:10.1210/en.2004-0765
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pauli, S. A.
Right arrow Articles by Zimmermann, R. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pauli, S. A.
Right arrow Articles by Zimmermann, R. C.
Endocrinology Vol. 146, No. 3 1301-1311
Copyright © 2005 by The Endocrine Society

The Vascular Endothelial Growth Factor (VEGF)/VEGF Receptor 2 Pathway Is Critical for Blood Vessel Survival in Corpora Lutea of Pregnancy in the Rodent

Samuel A. Pauli, Hongyan Tang, Jeff Wang, Peter Bohlen, Robert Posser, Tipton Hartman, Mark V. Sauer, Jan Kitajewski and Ralf C. Zimmermann

Department of Obstetrics and Gynecology, Yale University (S.A.P.), New Haven Connecticut 06520; Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology (H.T., J.W., R.P., T.H., M.V.S., J.K., R.C.Z.), Department of Pathology (J.K.), Columbia University, New York, New York 10032; and ImClone Systems Incorporated (P.B.), New York, New York 10014

Address all correspondence and requests for reprints to: Dr. Ralf C. Zimmermann, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology, Columbia University College of Physicians and Surgeons, PH-16, 630 West 168th Street, New York, New York 10032. E-mail: rcz3{at}columbia.edu.

The vascular endothelial growth factor (VEGF)/VEGF receptor 2 (VEGFR-2) pathway regulates proliferation, survival, and permeability of vasculature. This pathway is active during the formation of a corpus luteum, a highly vascularized, endocrine organ with a short life span during the nonpregnant state. In the pregnant state, the life span of corpora lutea is much longer because they play a critical role in supporting pregnancy development. We hypothesized that the VEGF/VEGFR-2 pathway plays a critical role in regulating angiogenic events in the corpora lutea of pregnancy. Injection of the neutralizing anti-VEGFR-2 antibody DC101 (ImClone Systems, Inc., New York, NY) on embryonic d 3.5 (preimplantation) or 6.5 (postimplantation) disrupts function of the corpora lutea of pregnancy in CD1 mice, as evidenced by a decrease in organ size, regression of luteal vessels, and a fall in progesterone secretion within 24 h postinjection. Inhibition of the VEGFR-2 caused removal of endothelial cells, mostly through endothelial cell detachment from the vascular basement membrane. Luteal steroid-producing epithelial cells were eliminated through apoptosis secondary to vasculature becoming dysfunctional. Disruption of luteal function caused arrest of embryonic development. The effect of antibody is specific to the ovary, because pregnancy progresses normally in ovariectomized, progesterone-replaced animals treated with anti-VEGFR-2 antibody. Embryonic blood vessels were not affected directly by the antibody, because it did not reach the embryo. Administration of an antibody against VE-cadherin (E4G10), which specifically blocks endothelial proliferation, did not disrupt luteal function and pregnancy development. Thus, VEGFR-2-mediated endothelial cell signals are critical to maintain functionality of luteal blood vessels during pregnancy. Potential clinical applications of inhibitors of the VEGF/VEGFR-2 pathway include emergency contraception and medical treatment of ectopic and abnormal intrauterine pregnancies.




This article has been cited by other articles:


Home page
Mol Hum ReprodHome page
A. Van Langendonckt, J. Donnez, S. Defrere, G. A.J. Dunselman, and P. G. Groothuis
Antiangiogenic and vascular-disrupting agents in endometriosis: pitfalls and promises
Mol. Hum. Reprod., May 1, 2008; 14(5): 259 - 268.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
S. R. Soares, R. Gomez, C. Simon, J. A. Garcia-Velasco, and A. Pellicer
Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome
Hum. Reprod. Update, April 2, 2008; (2008) dmn008v1.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
C. Alvarez, I. Alonso-Muriel, G. Garcia, J. Crespo, J. Bellver, C. Simon, and A. Pellicer
Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study
Hum. Reprod., December 1, 2007; 22(12): 3210 - 3214.
[Abstract] [Full Text] [PDF]


Home page
ReproductionHome page
J Sengupta, P G L Lalitkumar, A R Najwa, D S Charnock-Jones, A L Evans, A M Sharkey, S K Smith, and D Ghosh
Immunoneutralization of vascular endothelial growth factor inhibits pregnancy establishment in the rhesus monkey (Macaca mulatta)
Reproduction, June 1, 2007; 133(6): 1199 - 1211.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
C. Stocco, C. Telleria, and G. Gibori
The Molecular Control of Corpus Luteum Formation, Function, and Regression
Endocr. Rev., February 1, 2007; 28(1): 117 - 149.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
R. Gomez, M. Gonzalez-Izquierdo, R. C. Zimmermann, E. Novella-Maestre, I. Alonso-Muriel, J. Sanchez-Criado, J. Remohi, C. Simon, and A. Pellicer
Low-Dose Dopamine Agonist Administration Blocks Vascular Endothelial Growth Factor (VEGF)-Mediated Vascular Hyperpermeability without Altering VEGF Receptor 2-Dependent Luteal Angiogenesis in a Rat Ovarian Hyperstimulation Model
Endocrinology, November 1, 2006; 147(11): 5400 - 5411.
[Abstract] [Full Text] [PDF]


Home page
ReproductionHome page
H. M Fraser, H. Wilson, C. Wulff, J. S Rudge, and S. J Wiegand
Administration of vascular endothelial growth factor Trap during the 'post-angiogenic' period of the luteal phase causes rapid functional luteolysis and selective endothelial cell death in the marmoset.
Reproduction, October 1, 2006; 132(4): 589 - 600.
[Abstract] [Full Text] [PDF]


Home page
ReproductionHome page
J Aguilar, H M Fraser, H Wilson, E Clutton, D J Shaw, and E D Watson
Temporal relationship between proliferating and apoptotic hormone-producing and endothelial cells in the equine corpus luteum
Reproduction, July 1, 2006; 132(1): 111 - 118.
[Abstract] [Full Text] [PDF]


Home page
ReproductionHome page
A. Matsuoka-Sakata, H. Tamura, H. Asada, I. Miwa, T. Taketani, Y. Yamagata, and N. Sugino
Changes in vascular leakage and expression of angiopoietins in the corpus luteum during pregnancy in rats
Reproduction, February 1, 2006; 131(2): 351 - 360.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
M. Hsieh, D. Boerboom, M. Shimada, Y. Lo, A. F. Parlow, U. F.O. Luhmann, W. Berger, and J. S. Richards
Mice Null for Frizzled4 (Fzd4-/-) Are Infertile and Exhibit Impaired Corpora Lutea Formation and Function
Biol Reprod, December 1, 2005; 73(6): 1135 - 1146.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2005 by The Endocrine Society